Trial Profile
A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Rifampicin
- Indications Non-Hodgkin's lymphoma
- Focus Pharmacokinetics
- Sponsors AbbVie
- 23 May 2014 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 01 Nov 2013 New trial record